Various 1-and 2-substituted and 1,2-fused 1,4-dihydropyridine-5-phosphonate derivatives were designed and synthesized as analogues of 1,4-dihydropyridine-3,5-dicarboxylate, and their antihypertensive activities were examined. Several compounds proved to be equal or superior to nifedipine in lowering blood pressure in normotensive and spontaneously hypertensive rats. Among these compounds, 1-substituted 1,4-dihydropyridine derivatives showed potent antihypertensive activities. The structure-activity relationships are discussed.
In the previous paper,21 the authors reported the synthesis of 1,4-dihydropyridine-5-phosphonates (I) and the antihypertensive activities of these compounds, which were expected to have more prolonged calcium antagonistic activity and better bioavailability than nifedipine. Among them, methyl 2,6-dimethy1-4-(2-nitropheny1)-5-(2-oxo-1,3,2-dioxaphosphorinan-2-y1)-1,4-dihydropyridine-3-carboxylate (DHP-218), which is approximately 7 times more active than nifedipine and has long-lasting antihypertensive activity,3) was chosen for clinical evaluation.
Recently, various new 1-and 2-substituted 1,4-dihydropyridines have been reported. Flordipine is a first development dihydropyridine compound with a substituent on the nitrogen atom (1-position). It exhibits antihypertensive activity in rats and dogs when given by the oral route. FR-75345) and nilvadipine5a.6) are dihydropyridine-related compounds which are substituted in the 2-position with a hydroxymethyl and a cyano group, respectively, in place of the methyl group of nifedipine. Among them, nilvadipine, which shows longlasting antihypertensive activity, has been reported to be clinically effective. 2-Amino7) and 1,2-fused derivatives8) have also been synthesized and their antihypertensive activity examined. The former was active, but the latter was not.
In this paper, the synthesis and the antihypertensive activities of 1-and 2-substituted and 1,2-fused 1,4-dihydropyridine-5-phosphonate derivatives (II-IV) are described, and the structure-activity relationships of these compounds are discussed.
Chemistry
1-Substituted-1,4-dihydropyridine-5-phosphonates (II) The 1-substituted-1,4-dihydropyridines (II) listed in Table I were synthesized by the two routes shown in Chart 2. As described in the previous paper,2) the 1-arylideneacetonylphosphonates 42) were allowed to react with the appropriate N-substituted 3-aminocrotonates 3 in 2-propanol under reflux to afford II in 13-59% yields, except for compound 9 (R1: NMe2, 3%; method A). In this case, the reaction of 4 with N-isopropyl (3d) and N-methoxy 3-aminocrotonates (3q) did not afford treatment with hydroxylamine hydrochloride in the presence of sodium acetate in quantitative yields; the dehydration of 38a-c proceeded in good yields. The 2-amino-l ,4-dihydropyridines (41a-d) (R5: NH2) were synthesized through the route shown in Chart 4. The condensation of 4 with ethyl amidinoacetate hydrochloride (40) in ethanol under reflux gave the 2-amino compounds (41a-d) in 33-44% yields. The 2-amino compounds are presumed to exist as a tautomers (41A, B) from their proton nuclear magnetic resonance (1H-NMR) spectra, like the corresponding 3,5-dicarboxylate derivatives') (Chart 4), and were slightly unstable. described above. The dose (in mg/kg) which produced a 30% drop in blood pressure was calculated from the regression line as the ED30 value (Table VI) .
Results and Discussion
The antihypertensive activities of the new 1,4-dihydropyridines (II-IV) are shown in Tables I, III and IV. It is generally known that in 1,4-dihydropyridine-3,5-dicarboxylate derivatives, a substituent at the 1-position causes a decrease of the activity,") though flordipine is a potent antihypertensive agent. However, compounds II in our present study showed antihypertensive activity comparable to that of nifedipine.11) Thus, we suspected that the size of the 1-substituent influences the antihypertensive activity, and the activities are assumed to decrease in the following order: (R4); ethyl, methoxymethyl, methyl, propyl, allyl, 2-methoxyethyl, ethoxymethyl, benzyl, 2-morpholinoethyl, dimethylamino. Compound 16 with a 2-morpholinoethyl group as a phosphonate analogue of flordipine showed disappointingly low activity. The 1-methyl compound (7) exhibited activity about 20 times that of the corresponding 3, 5-dicarboxylate compound (33).
As regards the 2-substituted-1,4-dihydropyridines (III), compounds 39a and 39b with a 2-CN substituent were the most active. Those with 2-CH2OH and 2-NH2 substituents were moderately active. The 5-diallyl phosphonate compounds (39c, 41d) were less active than the 5-cyclic phosphonates (39a, 39b, 41a).
The 1,2-fused 1,4-dihydropyridines (IV), which were cyclized at the 1 and 2 positions of strongly active II (8, 9), were expected to be as active as the 1-and 2-substituted-1,4-dihydropyridines (II), but, contrary to expectation, they were all (44-52) inactive.
Next, the active 1,4-dihydropyridines (II and III) listed in Tables I and III were examined for antihypertensive activity in unanesthetized SHR. Among them, the seven compounds listed in Table V showed activities equal or superior to that of nifedipine. The antihypertensive activities of the most active compound (7) was approximately four times that of nifedipine and one-half that of DHP-218.
In general, the 1-substituted compounds had a strong and long-lasting antihypertensive activity, but the 2-substituted compounds showed a milder and longer-lasting activity than that of II (Fig. 1) . However, none of them was more active than DHP-218. Methyl 2-Cyano-6-methy1-4-(2-nitropheny1)-5-(2-oxo-1,3,2-dioxaphosphorinan-2-y1)-1,4-dihydropyridine-3-carboxylate (39a)
A solution of the above 38a (0.90 g) and CDI (1.0 g, 3 eq) in CH2C12 (15 ml) was refluxed with stirring for 2 d. When the reaction mixture was washed with aqueous HC1, the product crystallized out of the solution. The precipitated crystals were collected by filtration and washed with water to give 39a (0.557 g, 64.7%), which was recrystallized from AcOEt-methanol to yield 39a as yellow crystals (0. 
